

## United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO. FILING D		ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/054,534	10/054,534 01/22/2002		Pradip Mukerji	6763.US.P1	3165	
23492	7590	7590 02/22/2005		EXAMINER		
ROBERT	DEBERA		SULLIVAN,	SULLIVAN, DANIEL M		
	TT PARK	<del></del>	ART UNIT	PAPER NUMBER		
DEPT. 377	//AP6A		1636			
ABBOTT	PARK, IL	60064-6008		DATE MAILED: 02/22/2005	DATE MAILED: 02/22/2005	

Please find below and/or attached an Office communication concerning this application or proceeding.

## Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)		
10/054,534	MUKERJI ET AL.		
Examiner	Art Unit		
Daniel M Sullivan	1636		

		Artonic	1					
	Daniel M Sullivan	1636						
The MAILING DATE of this communication appears on the cover sheet with the correspondence address								
THE REPLY FILED 01 February 2005 FAILS TO PLACE THIS	APPLICATION IN CONDITION FO	R ALLOWANCE.						
<ol> <li>The reply was filed after a final rejection, but prior to filing must timely file one of the following replies: (1) an amend condition for allowance; (2) a Notice of Appeal (with appearamentation (RCE) in compliance with 37 CFR 1.114. The period for reply expiresmonths from the mailing</li> </ol>	Iment, affidavit, or other evidence, wat fee) in compliance with 37 CFR ereply must be filed within one of tog date of the final rejection.	which places the appl 41.31; or (3) a Reque he following time peri	ication in est for Continued ods:					
b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. I no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection.								
Examiner Note: If box 1 is checked, check either box (a) or TWO MONTHS OF THE FINAL REJECTION. See MPEP 7	06.07(f).							
Extensions of time may be obtained under 37 CFR 1.136(a). The date have been filed is the date for purposes of determining the period of ex under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the set forth in (b) above, if checked. Any reply received by the Office later may reduce any earned patent term adjustment. See 37 CFR 1.704(b) NOTICE OF APPEAL	tension and the corresponding amount shortened statutory period for reply origi r than three months after the mailing da	of the fee. The appropri	iate extension fee					
2. The reply was filed after the date of filing a Notice of Appewas filed on <u>01 February 2005</u> . A brief in compliance with Notice of Appeal (37 CFR 41.37(a)), or any extension the of Appeal has been filed, any reply must be filed within the <u>AMENDMENTS</u>	h 37 CFR 41.37 must be filed withir reof (37 CFR 41.37(e)), to avoid dis	n two months of the dissmissal of the appeal.	ate of filing the					
	but prior to the date of filing a brief	will not be entered by	ecause					
3. The proposed amendment(s) filed after a final rejection, but prior to the date of filing a brief, will <u>not</u> be entered because  (a) They raise new issues that would require further consideration and/or search (see NOTE below);  (b) They raise the issue of new matter (see NOTE below):								
(c) They are not deemed to place the application in being appeal; and/or		ducing or simplifying	the issues for					
(d) They present additional claims without canceling a		ected claims.						
NOTE: <u>See Continuation Sheet</u> . (See 37 CFR 1.1								
<ul> <li>4.  The amendments are not in compliance with 37 CFR 1.1</li> <li>5.  Applicant's reply has overcome the following rejection(s)</li> </ul>	:	·	,					
6. Newly proposed or amended claim(s) would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).								
7.  For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is protected. The status of the claim(s) is (or will be) as follows: Claim(s) allowed:	⊠ will not be entered, or b) □ wil vided below or appended.	l be entered and an e	xplanation of					
Claim(s) objected to:								
Claim(s) rejected: <u>2,4,5,11-16 and 36</u> . Claim(s) withdrawn from consideration: <u>1,6-10 and 17-35</u> .								
AFFIDAVIT OR OTHER EVIDENCE								
<ol> <li>The affidavit or other evidence filed after a final action, bu because applicant failed to provide a showing of good and was not earlier presented. See 37 CFR 1.116(e).</li> </ol>	t before or on the date of filing a No d sufficient reasons why the affidav	otice of Appeal will <u>no</u> it or other evidence is	t be entered necessary and					
9. The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to a showing a good and sufficient reasons why it is necessary.	vercome all rejections under appea	al and/or appellant fai	Is to provide a					
10. The affidavit or other evidence is entered. An explanation REQUEST FOR RECONSIDERATION/OTHER	n of the status of the claims after er	ntry is below or attach	ed.					
11. The request for reconsideration has been considered bu	t does NOT place the application in	condition for allowar	ice because:					
12. Note the attached Information Disclosure Statement(s).	(PTO/SB/08 or PTO-1449) Paper N	o(s)						
13.  Other:	4	DAVID GUZO PRIMARY EXAMINE						

Continuation of 3. NOTE: Claim 2, which was directed to an isolated nucleotide sequence comprising at least 70% nucleotide sequence identity to a nucleotide sequence comprising SEQ ID NO: 13, is amended such that it is now directed to an isolated nucleic acid sequence "encoding a polypeptide having at least 70% sequence identity to SEQ ID NO: 14, wherein said nucleic acid sequence encodes a functionally active D6-desaturase". The scope of the amended claim is significantly different from the scope of the examined claim because, due to the degeneracy of codon sequences, the genus of nucleic acids encoding a polypeptide having 70% identity with a reference polypeptide sequence is broader than the genus of nucleic acids having 70% identity with a reference nucleic acid sequence. Limitation of the claimed nucleic acid to encoding a functionally active D6-desaturase narrows the scope of the claim; however, it is not clear that a nucleic acid limited to having 70% sequence identity with SEQ ID NO: 13 would embrace all nucleic acids encoding a polypeptide having 70% identity with SEQ ID NO: 14 and exhibiting D6-desaturase activity. Although claim 36 was directed to a nucleic acid encoding a polypeptide having desaturase activity and at least 70% sequence identity with SEQ ID NO: 14, the polypeptide of the claim was also limited to having a third histidine box motif consisting essentially of QXXHH, while the amended claim 2 is not so limited. Thus, the scope of the amended claim 2 is different from, and appears to be broader than the scope of any of the previously examined claims. Therefore, entry of the proposed amendment would require additional consideration and/or search.

It is noted that the proposed amendments would appear to overcome the outstanding rejections with the exception of the double patenting rejection, which applicant has requested be held in abeyance until such time as allowable subject matter is indicated. It is further noted that, should Applicant file an amendment which places the product claims in condition for allowance, pursuant to the procedures set forth in the Official Gazette notice dated March 26, 1996 (1184 O.G. 86), process claims such as claims 25-30, will be rejoined IF THEY DEPEND FROM OR INCLUDE ALL OF THE LIMITATIONS OF THE ALLOWED PRODUCT CLAIMS. In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Amendments submitted after final rejection are governed by 37 CFR 1.116..